Related references
Note: Only part of the references are listed.The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma
Neta Goldschmidt et al.
ANNALS OF HEMATOLOGY (2011)
Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma
Alison J. Moskowitz et al.
BLOOD (2010)
Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma
Noemi Puig et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma
Andreas Josting et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma
Craig H. Moskowitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
CURRENT CONCEPTS Early-Stage Hodgkin's Lymphoma
James O. Armitage
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
Anas Younes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma
Marcel P. Devetten et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Allogeneic Stem Cell Transplantation Compared with Chemotherapy for Poor-Risk Hodgkin Lymphoma
Luca Castagna et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy
Luca Castagna et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Role of [18F] Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma
Pier Luigi Zinzani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant
Sonali M. Smith et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin Lymphoma
Lauri M. Burroughs et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma
Carsten Kobe et al.
BLOOD (2008)
Fludarabine-meiphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated MD Anderson Cancer Center experience
Paolo Anderlini et al.
HAEMATOLOGICA (2008)
Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: An analysis from the lymphoma working party of the European group for blood and marrow transplantation
Anna Sureda et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Risk-Adapted Salvage Treatment With Single or Tandem Autologous Stem-Cell Transplantation for First Relapse/Refractory Hodgkin's Lymphoma: Results of the Prospective Multicenter H96 Trial by the GELA/SFGM Study Group
Franck Morschhauser et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease
Christophe Ferme et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes
Karl S. Peggs et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients
S. Akhtar et al.
BONE MARROW TRANSPLANTATION (2007)
Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma
Elias Jabbour et al.
CANCER (2007)
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804
N. L. Bartlett et al.
ANNALS OF ONCOLOGY (2007)
Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma
Henry C. Fung et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma
A. M. Evens et al.
ANNALS OF ONCOLOGY (2007)
Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in lymphoma
Malik E. Juweid et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma
Bart W. Schot et al.
BLOOD (2007)
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma
Pier Luigi Zinzani et al.
HAEMATOLOGICA (2007)
A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma
J Kuruvilla et al.
HEMATOLOGY (2006)
Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma:: Results of a Spanish prospective cooperative protocol
I Alvarez et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2006)
Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma
J Kuruvilla et al.
CANCER (2006)
Long-term follow-up of salvage radiotherapy in Hodgkin's lymphoma after chemotherapy failure
B Campbell et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Salvage therapy of progressive and recurrent Hodgkin's disease:: Results from a multicenter study of the pediatric DAL/GPOH-HD study group
G Schellon et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens
KM Ardeshna et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation
KS Peggs et al.
LANCET (2005)
Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma:: A retrospective analysis from the German Hodgkin Lymphoma Study Group
A Josting et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG)
A Josting et al.
ANNALS OF ONCOLOGY (2005)
Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease
CH Moskowitz et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+cell dose, GVHD and disease response
P Anderlini et al.
BONE MARROW TRANSPLANTATION (2004)
Treatment for primary refractory Hodgkin's disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapy
J Czyz et al.
BONE MARROW TRANSPLANTATION (2004)
Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group
T Baetz et al.
ANNALS OF ONCOLOGY (2003)
A pilot study of rituximab in patients with recurrent, classic Hodgkin disease
A Younes et al.
CANCER (2003)
An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation
AJ Peniket et al.
BONE MARROW TRANSPLANTATION (2003)
Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma
I Chau et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Strategic approach to the management of Hodgkin's disease incorporating salvage therapy with high-dose ifosfamide, etoposide and epirubicin: a Northern Region Lymphoma Group study (UK)
SJ Proctor et al.
ANNALS OF ONCOLOGY (2003)
Time-intensified dexamethasone/cisplatin/cytarabine:: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease
A Josting et al.
ANNALS OF ONCOLOGY (2002)
The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation
PJ Bierman et al.
ANNALS OF ONCOLOGY (2002)
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease:: a randomised trial
N Schmitz et al.
LANCET (2002)
Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy:: Results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 trial
C Fermé et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group
A Josting et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Long-term results of blood and marrow transplantation for Hodgkin's lymphoma
G Akpek et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease
OW Press et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease
A Martín et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model
CH Moskowitz et al.
BLOOD (2001)
Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease
MJ Stuart et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2001)
Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation
DA Stewart et al.
BONE MARROW TRANSPLANTATION (2000)
Share Paper
